Don't forget Michael Moore's coming up on Larry King n/t

Thanks, m! I tuned in now.

Do your stuff.

Yesterday he said Cuba spent $25 per person.

:popcorn:

Smackdown time!

:popcorn:

Butter!! :rofl:

but gupta will get free wheeling time.

"The World Health Organization puts Cuba's per capita health spending at approximately $229 American dollars."

Moore just disagreed and said it was $251 on his website.

I don't know why those two are fighting about $22 !! Just say about $200

if only CNN could be so niggling about the bushies

health care.

So Sanjay was not being intellectually honest by claiming that Moore's number came from the BBC. It actually came from the UN report on Moore's website, which was cited by Newsnight.

larry's got publisher's clearing house to pimp. this is just more he said/he said. larry's trying to make this all opinion, like there's no actual facts.

remaining moments? it just started. i guess america's disasterous healthcare system is only worth 1/3 of a show.

Equal time is out the window.

insurance and pharma bullshit. Gupta wants a spinterview. He really thinks he's clever.

Who cares about fighting about little shit.

Bwaaaaaaaaaaaaaaaaaaah!! :rofl: :rofl:

CNN put his name up for about a nanosecond:

Paul H. Keckley is an active member of several societies and editorial boards, and has authored numerous articles and three books. He has been profiled by ABC’s 20/20, CBS’s 60 Minutes, Fox News, CNN, The Wall Street Journal, and has been featured as a keynote speaker at several national industry meetings. Dr. Keckley has also testified for state Medicaid Review Committees in Utah and Tennessee about the potential impact of evidence-based standards on benefits for enrollees.

http://www.prescienceintl.com/programs_bio_faculty.html

the phrase "evidence-based standards on benefits for enrollees" seemed to stick out to me and here's what i found:

http://en.wikipedia.org/wiki/Evidence-based_medicine

In managed healthcare systems, evidence-based guidelines have been used as a basis for denying insurance coverage for some treatments which are held by the physicians involved to be effective, but of which randomized controlled trials have not yet been published. In some cases, these denials were based upon questions of induction and efficacy as discussed above. For example, if an older generic statin drug has been shown to reduce mortality, is this enough evidence for use of a much more expensive newer statin drug which lowers cholesterol more effectively, but for which mortality reductions have not had time enough to be shown? If a new, costly therapy that works on tumor blood vessels causes two kinds of cancer to go into remission, is it justified as an expense in a third kind of cancer, before this has specifically been proven? Skepticism here has been easier for insurers. Kaiser Permanente did not change its methods of evaluating whether or not new therapies were too "experimental" to be covered, until it was successfully sued twice: once for delaying IVF treatments for two years after the courts determined that scientific evidence of efficacy and safety had reached the "reasonable" stage, and in another case where Kaiser refused to pay for liver transplantion in infants when it had already been shown to be effective in adults, on the basis that use in infants was still "experimental." Here again the problem of induction plays a key role in arguments.

Can't wait for the details on the expert.

:hi:

Edit: Never mind; it's working now.

works for Deloitte and Touche:

http://www.democraticunderground.com/discuss/duboard.php?az=show_mesg&forum=385&topic_id=39840&mesg_id=39840

Notice that in the interview with the Deloitte Health-Care Analyst guy, the 'analyst' says almost nothing, really, nothing anyone doesn't know and that wasn't addressed in 'Sicko.' People buy health care outside of the system in these other countries. Good. So what? These systems are paid for by taxes. We know! It says so in the movie. Jeez...!

By the way, about Deloitte, from their website:

Deloitte refers to one or more of Deloitte Touche Tohmatsu, a Swiss Verein, its member firms, and their respective subsidiaries and affiliates. Deloitte Touche Tohmatsu is an organization of member firms around the world devoted to excellence in providing professional services and advice, focused on client service through a global strategy executed locally in nearly 140 countries. With access to the deep intellectual capital of approximately 150,000 people worldwide, Deloitte delivers services in four professional areas — audit, tax, consulting, and financial advisory services — and serves more than 80 percent of the world’s largest companies, as well as large national enterprises, public institutions, locally important clients, and successful, fast-growing global growth companies. Services are not provided by the Deloitte Touche Tohmatsu Verein, and, for regulatory and other reasons, certain member firms do not provide services in all four professional areas.